Nurmi, E. L. http://orcid.org/0000-0003-4893-8957
Laughlin, C. P. http://orcid.org/0000-0002-5683-6881
de Wit, H. http://orcid.org/0000-0002-7211-8994
Palmer, A. A.
MacKillop, J. http://orcid.org/0000-0003-4118-9500
Cannon, T. D. http://orcid.org/0000-0002-5632-3154
Bilder, R. M. http://orcid.org/0000-0001-5085-7852
Congdon, E. http://orcid.org/0000-0003-2921-0944
Sabb, F. W.
Seaman, L. C.
McElroy, J. J. http://orcid.org/0009-0005-4785-8025
Libowitz, M. R.
Weafer, J. http://orcid.org/0000-0002-7849-9900
Gray, J. http://orcid.org/0000-0002-5351-561X
Dean, A. C.
Hellemann, G. S.
London, E. D. http://orcid.org/0000-0003-3577-7808
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R03MH112032-01A1, RL1MH083268, RL1MH083268, RL1MH083268, RL1MH083270, RL1LM009833, PL1MH083271, PL1NS062410, R01 DA032015, R01 DA032015)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA032015)
Peter Boris Chair in Addictions Research
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Thomas P and Katherine K Chair in Addiction Studies
Article History
Received: 31 October 2022
Revised: 3 May 2023
Accepted: 7 June 2023
First Online: 15 August 2023
Competing interests
: ELN is an unpaid member of the Tourette Association of America and Myriad Genetics Advisory Boards. JM is a principal in Beam Therapeutics, Inc. and a consultant to Clairvoyant Therapeutics, Inc. HdW. is a scientific advisor to Awakn Life Sciences and Gilgamesh Pharmaceutics, and on the Board of Directors of PharmAla Biotech.